Referenties

Bloom, R., & Amber, K. T. (2017). Identifying the incidence of rash, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients taking lamotrigine: a systematic review of 122 randomized controlled trials. An Bras Dermatol, 92(1), 139-141. doi: 10.1590/abd1806-4841.20175070. 

Chen, C. B., Hsiao, Y. H., Wu, T., Hsih, M. S., Tassaneeyakul, W., Jorns, T. P., . . . Chung, W. H. (2017). Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology, 88(1), 78-86. doi: 10.1212/wnl.0000000000003453. 

Farmacotherapeutisch Kompas. http://www.fk.cvz.nl/

Farmacotherapeutisch rapport brivaracetam (BriviactR) bij de behandeling van partiele epilepsie. Zorginstituut Nederland. 24 mei 2016

Powell, G., Saunders, M., Rigby, A., & Marson, A. G. (2016). Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. Cochrane Database Syst Rev, 12, Cd007124. doi: 10.1002/14651858.CD007124.pub5. 

Tassaneeyakul W, Tiamkao S, Jantararoungtong T, Chen P, Lin SY, Chen WH, Konyoung P, Khunarkornsiri U, Auvichayapat N, Pavakul K, Kulkantrakorn K, Choonhakarn C, Phonhiamhan S, Piyatrakul N, Aungaree T, Pongpakdee S, Yodnopaglaw P., (2010). Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia, 51(5), pp. 926-30.

Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, Perucca E, Vajda F; EURAP study group.,( 2011). Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet neurology, 10(7), pp. 609-617.

Zhu, L. N., Chen, D., Chen, T., Xu, D., Chen, S. H., & Liu, L. (2017). The adverse event profile of brivaracetam: A meta-analysis of randomized controlled trials. Seizure, 45, 7-16. doi: 10.1016/j.seizure.2016.11.008.